Introduction: We studied the effect of neoadjuvant chemotherapy (NAC) ± trastuzumab on the ductal carcinoma in situ (DCIS) component in patients with locally advanced breast cancer who achieved pathological complete response (pCR).
Methods: The diagnostic biopsies of 92 consecutive breast cancer patients that were treated with neoadjuvant chemotherapy (NAC) ± trastuzumab were evaluated for the presence of DCIS. Upon completion of NAC, the surgical specimens were evaluated for complete eradication of both the invasive and non-invasive cancer in the breast. The pretreatment mammograms were evaluated for the presence of microcalcifications and compared to the mammograms that were obtained upon completion of therapy prior to surgery.
Results: Thirty of 92 patients (33%) had a substantial component of DCIS in the pretreatment biopsy. Thirty nine patients (42%) achieved pCR: 22 (56%) following NAC + trastuzumab, 17 (32%) following chemotherapy only. Ten of 30 patients (33%) with DCIS component achieved pCR: 4 received chemotherapy only, in 6 trastuzumab was added. Multiple microcalcifications on the pretreatment mammograms were observed in 3 of 10 patients with DCIS who achieved pCR. No reduction in the area of calcifications was observed following NAC.
Conclusions: DCIS may be completely eradicated by NAC ± trastuzumab. However, associated microcalcifications probably persist. Patients with locally advanced breast cancer with substantial DCIS may still opt for NAC and breast conservation as the DCIS component may respond and even completely disappear following NAC. Residual widespread microcalcifications after NAC do not necessarily indicate residual cancer. Larger studies are needed to direct the surgical management of these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejso.2017.04.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TFEB triggers a matrix degradation and invasion program in triple-negative breast cancer cells upon mTORC1 repression.
Dev Cell
December 2024
Institut Curie, CNRS UMR 144, PSL University, 75005 Paris, France. Electronic address:
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently hyperactivated in triple-negative breast cancers (TNBCs) associated with poor prognosis and is a therapeutic target in breast cancer management. Here, we describe the effects of repression of mTOR-containing complex 1 (mTORC1) through knockdown of several key mTORC1 components or with mTOR inhibitors used in cancer therapy. mTORC1 repression results in an ∼10-fold increase in extracellular matrix proteolytic degradation.
View Article and Find Full Text PDFComparison of the Structural, Cytological and Biomarker Expression in Carcinoma in situ and Invasive Components in Breast Carcinoma.
Iran J Pathol
April 2024
Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Background & Objective: Breast cancer is thought to arise from non-invasive breast lesions, such as atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS). DCIS is considered a direct precursor of invasive carcinoma. The morphological features alone do not reflect the biological truth of this disease.
View Article and Find Full Text PDFThe diagnostic value of contrast-enhanced ultrasound combined with clinicopathological features in microinvasive ductal carcinoma .
Gland Surg
November 2024
Department of Ultrasound, Chinese People's Liberation Army General Hospital, Beijing, China.
Background: Ductal carcinoma in situ with microinvasion (DCISM) represents 1% of all breast cancer cases and is arguably a more aggressive subtype of ductal carcinoma in situ (DCIS). Preoperative evaluation of DCISM usually relies on core needle biopsy, and non-invasive evaluation methods are relatively limited. This study aims to explore the features of conventional ultrasound (US) and contrast-enhanced ultrasound (CEUS) in DCISM and to analyze the US and clinicopathological predictors of infiltrating components.
View Article and Find Full Text PDFPrognostic implications of ductal carcinoma components in -positive breast cancer: a retrospective cohort study.
Ann Surg Treat Res
December 2024
Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Purpose: Although the breast cancer susceptibility gene -associated invasive breast cancer is well studied, there are limited reports on ductal carcinoma (DCIS) in patients with mutations. This study aims to evaluate the differential prognostic effect of DCIS in breast cancer patients with pathologic variants of genes.
Methods: Breast cancer patients who tested positive for mutations between August 2003 and January 2022 at a single tertiary referral center were retrospectively analyzed.
Surgical treatment after neoadjuvant systemic therapy for HER2-positive invasive breast cancer in the Netherlands: 10-Year trends and the influence an accompanying DCIS component.
Breast
November 2024
Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands.
Background: The presence of a DCIS component accompanying invasive breast cancer (IBC) is associated with a higher rate of primary mastectomy compared to IBC without DCIS. After neoadjuvant systemic therapy (NST), HER2+ IBC patients show high response rates, allowing for increasing breast-conserving surgery rates. The aim of this study was to examine surgical trends after NST in a Dutch nationwide HER2+ cohort, and the influence of a DCIS component on mastectomy rate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!